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HIV Resistance and Care Update

Objectives
• Summarize the HIV replicative cycle
• Describe the mechanism of action of ARVs
• Visualize how mutations & resistance occurs 
• Define current HIV treatment guidelines
• Illustrate resistance via clinical case presentations
No Disclosures
https://www.hiv.uw.edu/go/antiretroviral-therapy/general-information/core-concept/all#hiv-life-cycle-antiretroviral-drug-targets
https://youtu.be/PlSvywlLuNw
https://www.hiv.uw.edu/go/antiretroviral-therapy/general-information/core-
concept/all#hiv-life-cycle-antiretroviral-drug-targets
Resistance to maraviroc can occur when R5-tropic HIV-1 develops mutations that facilitate the gp120-CCR5 coreceptor 
binding despite maraviroc attachment to the CCR5 coreceptor and receptor conformational changes. When this type of 
resistance occurs, the binding of HIV-1 gp120 occurs with enhanced affinity at the CCR5 N-terminal domain region
NRTIs mimic human nucleotides and can 
be interchangeably taken up by reverse 
transcriptase. Unlike the human 
nucleotides, the NRTI medications do not 
have a 3'-hydroxyl group and additional 
nucleotides can not be added to the NRTI 
drug, hence the name chain terminator
High Error Rate with 
HIV Reverse Transcription
https://www.hiv.uw.edu/go/antiretroviral-therapy/evaluation-management-virologic-failure/core-concept/all
Discriminatory mutations allow the reverse 
transcriptase enzyme to preferentially select the 
naturally occurring deoxynucleotides present in 
the cell, thereby creating a relative decrease in 
the incorporation of the NRTI-triphosphate into 
the elongating HIV DNA strand.
K65R, K70E, L74V, M184I/V,  Q151M 
(A62V, V75I, F77L,  F116Y)
Excision mutations e hance the 
phosphorolytic excisi n of the NRTI-
triphosphate already added t  th  elongation 
HIV RNA-DNA omplex, resulting in 
unblocking of the primer by the NRTI.
M41L, D67N, K70R, 
L210W, T215Y/F, K219Q/E
NNRTIs bind to a 
hydrophobic pocket in the 
p66 subunit, which is in 
close proximity to the 
active polymerase site
Key binding pocket amino acids:
L100, K101, K103, V106, T107, 
V108, V179, Y181, Y188, V189, 
G190, F227, W229, L234, Y318 
(of p66), & E138 (of p51)
HIV integrase inhibitors 
utilize multiple mechanism 
to block the integrase 
strand transfer step and 
are thus referred to as 
integrase strand transfer 
inhibitors (INSTIs)
https://www.hiv.uw.edu/go/antiretroviral-therapy/evaluation-management-virologic-failure/core-concept/all
HIV protease 
inhibitors bind to the 
active site of HIV 
protease and inhibit 
the protease 
enzyme activity.
Mo e mutations are selected by PIs than by 
any other class and multiple protease 
mutations re required to significantly impact 
the virologic response to a ritonavir-boosted PI

Major Mutations
https://hivdb.stanford.edu/pages/download/resistanceMutations_handout.pdf
https://www.iasusa.org/sites/default/files/2017-drug-resistance-mutations-hiv-1-figure.pdf
• Lamivudine, Zidovudine
– Combivir™ (gen) $931.61
• Abacavir, Lamivudine
– Epzicom™ $1,416.35
• Emtricitabine, Tenofovir (TDF)
– Truvada™ $1,539.90
• Emtriva, Tenofovir Alafenamide (TAF)
– Descovy™ $1,759.73
• Abacavir, Zidovudine, Lamivudine
– Trizivir™ (gen) $1,738.46
• Efavirenz, Emtriva, TDF
– Atripla™ $2,551.99
• Rilpivirine, Emtriva, TDF
– Complera™ $2,463.37
• Emtriva, Rilpivirine, TAF 
• Odefsey™ $2,815.04
• Elvitegravir, cobi, Emtriva, TDF
– Stribild™ $2,948.70
• Elvitegravir, cobi, Emtriva, TAF
• Genvoya™ $4,182.52
• Dolutegravir, Abacavir, Lamivudine
• Triumeq™ $2,648.84
• Darunavir, Cobicistat
• Prezcobix™  $1,725.29
• Atazanavir, Cobicistat
• EvoTaz™ $1,684.44
• Dolutegravir, Rilpivirine
• Juluca™ $2,583.33
• Bictegravir, Emtriva, TAF
• Biktarvy™ $2,945.65
• Darunavir, cobi, Emtriva, TAF
• Symtuza™ $3,482.00
• Doravirine, lamivudine, TDF
• Delstrigo™ $2,100.00
July 18, 2018: Symtuza™ FDA Approved
Aug. 30, 2018: Delstrigo™ / Pifeltro™ (doravirine) 

Bictegravir/Emtricitabine/Tenofovir Alafenamide
On the basis of clinical trial results, the 
Panel classifies BIC/TAF/FTC as one of 
the Recommended Initial Regimens for 
Most Adults with HIV (Mar. 27, 2018)



Ibalizumab-uiyk
Trogarzo™
• CD4-directed post-attachment HIV-1 inhibitor (CCR5 & CXCR4)
– required for the entry of HIV-1 virus particles into host cells
– recombinant humanized monoclonal antibody
• Loading dose: 2,000mg / Maintenance: 800mg every 2 wks 
– 4 vials: dilution in 250mL of 0.9% Sodium Chloride Injection
– Infuse over 15-30 minutes
– Observe 1 hour after administration for the first infusion
– No RXN: can be reduced to 15 minutes thereafter
• Heavily treatment-experienced adults;
– multidrug resistant HIV-1 infection / failing current ARVs 
• Most common adverse reactions
– Diarrhea (8%), dizziness (8%), nausea (5%), rash (5%)
Trial TMB 301 Virologic Outcomes 
(Snapshot Algorithm) at Week 25
wholesale acquisition cost of $118,000/year
https://www.youtube.com/watch?v=rPf9rqBbrNQ&feature=youtu.be&t=07s


DHHS 2017 Guidelines
June 4: Prezcobix
March 18, 2018 
FDA Drug Safety Alert
Botswana identified neural tube defects in 4 infants born to 426 women who initiated a DTG-
based regimen prior to pregnancy, & who were still receiving it at the time of conception
https://www.cdc.gov/ncbddd/birthdefects/data.html
http://www.who.int/bulletin/volumes/94/1/14-151365/en/
Preliminary Data Suggest Increased Risk of Neural Tube Defects (NTDs) 
With Dolutegravir (DTG) Exposure at Conception
Tsepamo: birth outcomes surveillance study / Summary of Key Conclusions
• Unplanned analysis of ongoing birth outcomes surveillance study among Botswanan 
women with and without HIV infection detected preliminary increase in prevalence of
NTDs among infants exposed to DTG at conception
•NTD prevalence: DTG exposure at conception: 4/426 (0.94%; 95% CI: 0.37% - 2.4%)
•1 case each- encephalocele, anencephaly, myelomeningocele, iniencephaly
• NTD prevalence: other subgroups
• non-DTG ART at conception (0.12%), efavirenz at conception (0.05%), 
• DTG started during pregnancy (0.00%), and HIV-negative women (0.09%)
• At latest analysis, July 2018:
• NTD prevalence: DTG exposure at conception: 4/596 (0.67%; 95% CI: 0.26% - 1.7%)
• NTD prevalence: DTG started in pregnancy: 1/3104 (0.03%; 95% CI: 0.01% - 0.18%)
Investigators suggest that this preliminary, early signal needs further data and analysis
Source: 22nd International AIDS Conference
Released: July 27, 2018

Number 1
• 45 yo TGF transferring care; diagnosed with HIV 7 years ago
– Client unaware of what ARVs she has “been on” in the past
– Reports taking one pill a day
• Genotype demonstrates: L10I, K103N
• HIV-VL: 120,000
• CD4: 184 / 14%
• CBC/CMP: WNL
What should we do at this time?
A. Start Azithromycin, Bactrim DS & Atripla™
B. Start Bactrim DS & Complera™
C. Start Triumeq™
D. Start Bactrim DS & Genvoya™
E. Start Bactrim DS & hold ARVs for now
F. Watch & Wait
Mutations: L10I, K103N
HIV-VL: 120,000
CD4: 184 / 14%
Genotype: genetic code of the sample virus is compared to the wild type
Phenotype: sample of HIV is grown with each ARV
http://hivdb.stanford.edu/
http://www.iasusa.org/resistance_mutations
Acknowledgment: Elizabeth Race, MD MPH 
Records Arrive
Genotype:
– M184V, P225H
Mutations: L10I, K103N, M184V, P225H
HIV-VL: 120,000
CD4: 184 / 14%
What do we do now?
A. Refer or call someone
B. Bactrim DS & Symtuza™
C. Bactrim DS & Stribild™ 
D. Bactrim DS & Review Stanford HIV Database
E. Watch & Wait
Mutations: L10I, K103N, M184V, P225H, 84V, 63P, 190Q, 65N
HIV-VL: 120,000
CD4: 184 / 14%
The next day additional records arrive
84V, 63P, 190Q, 65N
Mutations: L10I, K103N, M184V, P225H,   
84V, 63P, 190Q, 65N
HIV-VL: 120,000
CD4: 184 / 14%
Number 2
• 38 yo AAM entering into care
– Client unaware of what ARVs he has “been on” in the past
– Reports taking several types of pills over the years with many SEs
– Points to: AZT, CBV, TDF, Truvada, Kaletra, DTG, Descovy, Evotaz
• Archive genotype demonstrates: 
– 36I, 62V, 219Q, 138A, 179D, 190A, 318F, 101Q, 143C, 230R
• HIV-VL: 98,000
• CD4: 86 / 4.1%
• eGFR: 61
What should we do at this time?
A. Refer or call someone else
B. Start Azithromycin, Bactrim DS & Biktarvy™
C. Start Bactrim, Descovy™ & Evotaz™
D. Start Bactrim DS & review Stanford HIV DB
E. Start Bactrim & Watch & Wait
Archive genotype demonstrates: 
36I, 62V, 219Q, 138A, 179D, 190A, 318F, 101Q, 143C, 230R
HIV-VL: 98,000
CD4: 86 / 4.1%
eGFR: 61
Mutations Review
Chart Review: Records Obtained
CCC called: Descovy™ + Prezcobix™
HIV-VL decr. to 26,000
CD4: 132/6%
Review of all available (R) tests (archived):
36I, 62V, 63P/S, 65R, 184I/V, 219Q, 138A, 179D, 190A, 
230L, 318F, 101Q, 103R, 143C, 230R, 74M, 151I
Repeat resistance testing without new mutations
What should we do at this time?
A. Refer or call someone else
B. Start Azithromycin, Bactrim DS & Biktarvy™
C. Start Bactrim, Genvoya™ & Prezista™
D. Start Bactrim DS & review Stanford HIV DB
E. Start Bactrim & Watch & Wait
Mutations: 36I, 62V, 63P/S, 65R, 184I/V, 
219Q, 138A, 179D, 190A, 230L, 318F, 
101Q, 103R, 143C, 230R, 74M, 151I
HIV-VL: 26,000
CD4: 132 / 6%
eGFR: 61
Descovy + Prezcobix: TDF (60), FTC (95), DRV (0) – monotherapy
Changed ARVs: AZT (-10: close monitoring), Prezcobix (0) + DTG (30: twice day)
Follow-up: HIV-VL: <40 and CD4: 201/12%. eGFR: 70, Hgb: 13.7
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